Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Baxter
UBS
Cantor Fitzgerald
Fish and Richardson
Cerilliant
Farmers Insurance
Julphar

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,426,423

« Back to Dashboard

Title:Method of treating Attention Deficit Hyper-Activity Disorder
Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
Inventor(s): Jordan; Shaun (Germantown, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita-cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo, JP)
Filing Date:Oct 31, 2007
Application Number:11/932,795
Claims:1. A method of treating a patient suffering from attention deficient hyper-activity disorder (ADHD), which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt, or solvate thereof selected from hemihydrates, hydrates, and alcoholates, wherein said patient is a mammal: ##STR00003## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

2. A method of treating a patient suffering from attention deficient hyper-activity disorder (ADHD), which comprises administering to said patient a therapeutically effective amount of a carbostyril compound, or a pharmaceutically acceptable salt, or solvate thereof selected from hemihydrates, hydrates, and alcoholates, wherein said patient is a mammal and wherein the carbostyril compound is 7-{4-[4(2,3 dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
Queensland Health
Harvard Business School
Boehringer Ingelheim
Dow
Fish and Richardson
AstraZeneca
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.